CL2019000909A1 - Métodos para reducir la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. - Google Patents

Métodos para reducir la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a.

Info

Publication number
CL2019000909A1
CL2019000909A1 CL2019000909A CL2019000909A CL2019000909A1 CL 2019000909 A1 CL2019000909 A1 CL 2019000909A1 CL 2019000909 A CL2019000909 A CL 2019000909A CL 2019000909 A CL2019000909 A CL 2019000909A CL 2019000909 A1 CL2019000909 A1 CL 2019000909A1
Authority
CL
Chile
Prior art keywords
methods
human subject
subject suffering
reduce proteinuria
immunoglobulin nephropathy
Prior art date
Application number
CL2019000909A
Other languages
English (en)
Spanish (es)
Inventor
Gregory A Demopulos
Hans-Wilhelm Schwaeble
Nigel John Brunskill
Tom Dudler
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of CL2019000909A1 publication Critical patent/CL2019000909A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
CL2019000909A 2016-10-13 2019-04-04 Métodos para reducir la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. CL2019000909A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P 2017-06-30 2017-06-30

Publications (1)

Publication Number Publication Date
CL2019000909A1 true CL2019000909A1 (es) 2019-06-14

Family

ID=61906454

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019000909A CL2019000909A1 (es) 2016-10-13 2019-04-04 Métodos para reducir la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a.
CL2019003485A CL2019003485A1 (es) 2016-10-13 2019-11-28 Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019003485A CL2019003485A1 (es) 2016-10-13 2019-11-28 Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909)

Country Status (18)

Country Link
EP (1) EP3525798A4 (fr)
JP (1) JP6893554B2 (fr)
KR (1) KR102348939B1 (fr)
CN (2) CN110177557A (fr)
AU (1) AU2017342428B2 (fr)
BR (1) BR112019007426A2 (fr)
CA (2) CA3039927C (fr)
CL (2) CL2019000909A1 (fr)
GE (1) GEP20247587B (fr)
IL (1) IL265981A (fr)
JO (1) JOP20190068A1 (fr)
MA (1) MA46541A (fr)
MX (1) MX2019004074A (fr)
PH (1) PH12019500711A1 (fr)
SG (1) SG11201902941UA (fr)
UA (1) UA126908C2 (fr)
WO (1) WO2018071701A1 (fr)
ZA (1) ZA201902933B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CA3240483A1 (fr) 2021-12-10 2023-06-15 Thomas Dudler Anticorps therapeutiques qui se lient au domaine serine protease de masp-2 et leurs utilisations
CN117016486B (zh) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2374819T (pt) * 2003-05-12 2017-07-04 Helion Biotech Aps Anticorpos para masp-2
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7626730B2 (en) * 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
PT2488203T (pt) * 2009-10-16 2017-03-10 Univ Leicester Métodos para tratamento de coagulação intravascular disseminada através da inibição da activação do complemento dependente de masp-2
WO2012100262A1 (fr) * 2011-01-21 2012-07-26 Fibrogen, Inc. Méthode thérapeutique utilisant un anticorps anti-ctgf
CA3076975C (fr) * 2011-04-08 2024-06-18 Omeros Corporation Methodes de traitement d'etats associes a une activation du complement dependant dr masp-2
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CA3131223C (fr) * 2011-05-04 2024-01-30 Omeros Corporation Compositions pour inhiber l'activation de complement dependant de masp-2
CA2906096C (fr) * 2013-03-15 2022-03-15 Omeros Corporation Methodes de generation d'anticorps porteurs de peptide bioactif et compositions les comprenant
SI3057993T1 (sl) * 2013-10-17 2021-03-31 Omeros Corporation Postopki za zdravljenje bolezenskih stanj, povezanih z aktivacijo komplementov, odvisnih od MASP-2
CN117503923A (zh) * 2016-01-05 2024-02-06 莱斯特大学 用于抑制有需要的受试者的纤维化的方法
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق

Also Published As

Publication number Publication date
EP3525798A1 (fr) 2019-08-21
SG11201902941UA (en) 2019-05-30
MA46541A (fr) 2019-08-21
JP2019534271A (ja) 2019-11-28
MX2019004074A (es) 2019-06-10
CN116726163A (zh) 2023-09-12
EP3525798A4 (fr) 2020-07-08
KR102348939B1 (ko) 2022-01-12
PH12019500711A1 (en) 2019-11-18
CA3039927A1 (fr) 2018-04-19
GEP20247587B (en) 2024-01-25
KR20190063475A (ko) 2019-06-07
NZ753260A (en) 2021-11-26
ZA201902933B (en) 2023-05-31
CA3210384A1 (fr) 2018-04-19
CL2019003485A1 (es) 2020-04-13
BR112019007426A2 (pt) 2019-07-02
JP6893554B2 (ja) 2021-06-23
AU2017342428B2 (en) 2021-02-04
CA3039927C (fr) 2023-10-10
UA126908C2 (uk) 2023-02-22
AU2017342428A1 (en) 2019-05-23
WO2018071701A1 (fr) 2018-04-19
JOP20190068A1 (ar) 2019-04-01
CN110177557A (zh) 2019-08-27
IL265981A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
CL2019000909A1 (es) Métodos para reducir la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a.
CL2018001817A1 (es) Métodos para la inhibición de la fibrosis en un sujeto en necesidad de ellos
CL2017000558A1 (es) Terapia de combinación
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
CL2017002401A1 (es) Anticuerpos contra icos
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
CL2017001924A1 (es) Anticuerpos anti-transtiretina
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
CO2017003490A2 (es) Moléculas de anticuerpos a pd-l1
CU24498B1 (es) Anticuerpos de factor xi
CL2017003255A1 (es) Terapias de combinación para males hematologicos con anticuerpos anti-cd38 e inhibidores de survivin.
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CR20190271A (es) Anticuerpos antitau y métodos de uso
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
CU24427B1 (es) Moléculas de anticuerpo que se unen a tim-3
CO2017008482A2 (es) Anticuerpos anti-transtiretina
CO2017008469A2 (es) Anticuerpos anti-transtiretina
CO2018012987A2 (es) Anticuerpos que reconocen tau
CL2019000799A1 (es) Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano. (divisional solicitud 201602433)
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN